Enisa Zaric, MD

Montenegro

Specialist

Clinical Center of Montenegro, Center of Hematology

Department of Internal Medicine

Ljubljanska bb

81000 Podgorica, Montenegro

Phone: +38-2-20412462, +38-2-67611800

Email 1: enisazaric@yahoo.com

Email 2: enisazaric@gmail.com

©2010 Genentech USA, Inc.

GA10000083800

Pregnancy after the treatment of the primary

ovary Non Hodgkin lymphoma

MSc Enisa Žarić

Center for hematology,Clinical Center of Montenegro

Montenegro

3

Clinical presentation and history

28-years-old-woman , without previous disease

Patient presentation

Complained of pain in both inguinal regions for six months, night sweats, irregular menstrual bleeding. (since november 2009.)

Gynecology examinations: bimanual pelvic examination, ultrasound examination: showed a tumor mass in the right adnexa. Serum tumor markers were within reference range.

Laparascopic right oophorectomy performed (december 2009.)

Histopathology finding: Non Hodgkin follicular lymphoma (grade 3)

Immunohistochemistry studies: CK-, LCA +, CD30-, CD20+++, CD79α+, anti LCA+, CD10+, EMA-, CD5 -, bcl2 +, bcl6+, CD43-, CD23-, CD21-, MUM 1 +/-, anti CD3 -, antiCD43+, CD23-, Ki 67 index 30-40%.

4

Clinical presentation and historyClinical examination, labarotory and imaging findings (march 2010.):

Physical exam: no enlargement of lymph nodes, no organomegaly, no others abnormal findings

Blood counts: normal

Laboratory results: lactate dehydrogenase 139 ( upper limit 460)

Imaging studies:

ultrasound: no inguinal lymphadenopathy, and abdomen -ultrasound: no lymphadenopathy or other abnormal findings

PET CT – negative , ( PET CT Center Linz, Austria, february 2010.)

5

Diagnosis, objectives of treatment, treatment

DIAGNOSIS:

Non Hodgkin lymphoma Clinical Stage IE, follicular grade 3 (ovary)

FLIPI SCORE: 0

OBJECTIVES:

Physician’s treatment objective: Complete remission of disease

Patient’s objective: good quality of life allowing her to work and plan her family

TREATMENT: first-line R-CHOP, 6 cycles, every 21 days

( Rituximab i.v.(375 mg/m2 d0), Cyclophosphamide i.v. ( 750 mg/ m² d1) , Adriablastin (50 mg/m2, d1), Oncovin 2 mg i.v. (d1), Pronison 40+40+20 mg p.o. (d1-d5).

6

Outcome

After 4 cycles were administered:

Patient without symptoms

blood count and laboratory results were within normal limits

Imaging studies (ultrasound of peripheral regions): without lymphadenopathy and other abnormal findings

Bone marrow biopsy have not been done( technical reason)

No infections or immuno-chemotherapy side effects

6 cycles were administered finally on 22.6.2010.:

Previous results including

PET-CT there is no appreciable evidence of abnormal lesion in regions, specially not related to the primary diagnosis

7

Further case information / follow-up

Maintenance therapy with Rutiximab, 4 cycles every 2 months, (finally with 22.02.2011.)

Further follow up: at 3-month intervals for the two year, twice a year for the third and fourth years

Follow-up visits include interval history, careful physical examination, laboratory studies including a complete blood count, chemistry screen, and serum lactate dehydrogenase level, image studies including at times NMR of abdomen and pelvis, also PET CT

4 years follow up- no signs of disease

March 2015. delivery of a healthy female child

Good course of the pregnancy, vaginal delivery

Physician’s objective met: Complete remission of disease

Patient’s objectivemet : to be healthy, allowing her to work and plan her family

8

Literature data

Primary ovarian NHL is an extremely rare disease as other primary lymphomas of the genital tract, accounting for 0.5% of all NHLs and 1.5% of all malignant ovarian neoplasms. [1]

The most common type of lymphoma involving the ovary is diffuse large B-cell lymphoma. [2]

The initial clinical manifestation of an occult nodal lymphoma as an ovarian mass is known as having a poor outcome with a survival rate ranging from 7% to 38% at 5 years. But primary ovarian lymphoma has better prognosis. [3]

The histologic type of ovary lymphoma is probably the most important prognostic factor being associated with longer survival. [4]

In our case R-CHOP regimen, also according literature, was useful and well tolerated by the patient. [5,6]

1.Y. Yildirim, “Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate,” Gynecologic Oncology, vol. 97, no. 1, pp. 249–252, 2005. 2.R. Vang, et all, “Ovarian non-Hodgkin's lymphoma: a clinicopathologic study of eight primary cases,” Modern Pathology, vol. 14, no. 11, pp. 1093–1099, 2001. 3. S. Weingertner, et all, “Non-Hodgkin malignant lymphoma revealed by an ovarian tumor: case report and review of the literature,” Gynecologic Oncology, vol. 95, no. 3, pp. 750–754, 2004. 4.T. Yamada, et all, “A case of malignant lymphoma of the ovary manifesting like an advanced ovarian cancer,” Gynecologic Oncology, vol. 90, no. 1, pp. 215–219, 20035. Taylan Senol, et all, “ Five cases of Non-Hodgkin B-Cell Lymphoma of the Ovary ”Case Reports in Obstetrics and Gynecology, Volume 2014 (2014), Article ID 392758, 5 pages6.T. Yamada, et all, “A case of malignant lymphoma of the ovary manifesting like an advanced ovarian cancer,” Gynecologic Oncology, vol. 90, no. 1, pp. 215–219, 2003.

9

Dillemas and questions

Was it good choice of therapy?

How many cycles of therapy were optimal and what about maintenance therapy?

What is proposal for shortest period of time free of therapy for safe pregnancy planning, and should it be counted related to immuno-chemotherapy or end of maintenance therapy?

.